BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28778937)

  • 1. Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer.
    Bredemeier M; Edimiris P; Mach P; Kubista M; Sjöback R; Rohlova E; Kolostova K; Hauch S; Aktas B; Tewes M; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2017 Oct; 63(10):1585-1593. PubMed ID: 28778937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
    Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
    Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
    Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success.
    Ušiaková Z; Mikulová V; Pintérová D; Brychta M; Valchář J; Kubecová M; Tesařová P; Bobek V; Kološtová K
    In Vivo; 2014; 28(4):605-14. PubMed ID: 24982230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer.
    Davis AA; Zhang Q; Gerratana L; Shah AN; Zhan Y; Qiang W; Finkelman BS; Flaum L; Behdad A; Gradishar WJ; Platanias LC; Cristofanilli M
    Breast Cancer Res; 2019 Dec; 21(1):137. PubMed ID: 31801599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance).
    Magbanua MJM; Rugo HS; Wolf DM; Hauranieh L; Roy R; Pendyala P; Sosa EV; Scott JH; Lee JS; Pitcher B; Hyslop T; Barry WT; Isakoff SJ; Dickler M; Van't Veer L; Park JW
    Clin Cancer Res; 2018 Mar; 24(6):1486-1499. PubMed ID: 29311117
    [No Abstract]   [Full Text] [Related]  

  • 7. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
    Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
    Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
    Königsberg R; Obermayr E; Bises G; Pfeiler G; Gneist M; Wrba F; de Santis M; Zeillinger R; Hudec M; Dittrich C
    Acta Oncol; 2011 Jun; 50(5):700-10. PubMed ID: 21261508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease.
    Matuschek C; Bölke E; Lammering G; Gerber PA; Peiper M; Budach W; Taskin H; Prisack HB; Schieren G; Orth K; Bojar H
    Eur J Med Res; 2010; 15(7):277-86. PubMed ID: 20696638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay.
    Markou A; Strati A; Malamos N; Georgoulias V; Lianidou ES
    Clin Chem; 2011 Mar; 57(3):421-30. PubMed ID: 21245367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
    Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
    Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells.
    Gorges TM; Kuske A; Röck K; Mauermann O; Müller V; Peine S; Verpoort K; Novosadova V; Kubista M; Riethdorf S; Pantel K
    Clin Chem; 2016 Nov; 62(11):1504-1515. PubMed ID: 27630154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer.
    Strati A; Zavridou M; Kallergi G; Politaki E; Kuske A; Gorges TM; Riethdorf S; Joosse SA; Koch C; Bohnen AL; Mueller V; Koutsodontis G; Kontopodis E; Poulakaki N; Psyrri A; Mavroudis D; Georgoulias V; Pantel K; Lianidou ES
    Clin Chem; 2021 Oct; 67(10):1395-1405. PubMed ID: 34322698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients.
    Wang XM; Zhang Z; Pan LH; Cao XC; Xiao C
    Breast Cancer Res Treat; 2019 Apr; 174(2):375-385. PubMed ID: 30535933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
    Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
    Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer.
    Fina E; Reduzzi C; Motta R; Di Cosimo S; Bianchi G; Martinetti A; Wechsler J; Cappelletti V; Daidone MG
    Int J Biol Markers; 2015 Nov; 30(4):e429-33. PubMed ID: 26349664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.